All News

Interest in omega-3 fatty acids have increased since publication of the results of REDUCE-IT.

Researchers found underlying associations of insomnia with heart disease and stroke.

Despite advances in therapies for diabetes, those living with the disease are not faring better in reaching treatment targets due to lack of access to care, starting with the ability to be properly diagnosed.

While pulmonary rehabilitation (PR) is an evidence-based and cost-effective treatment for people with chronic obstructive pulmonary disease (COPD), uptake of and compliance with this intervention has been poor. For patients who decline PR, inspiratory muscle training (IMT), which involves strengthening the inspiratory muscles by increasing their workload, may be an option, particularly as it can be performed in the home instead of in a clinic.

Blood clots, or venous thromboembolism, remains a leading causes of death and healthcare spending in patients with cancer.

Researchers said taking genetic variability into account in the future will be helpful not only to understand the course of Parkinson disease but also to minimize heterogeneity in clinical trials.

The panel voted against recommending the prevention pill for use in cisgender women due to inadequate data on efficacy in this patient population.

A psoriasis researcher discusses a new class of psoriasis treatments.

This week, the top managed care stories included the Trump administration looking to bar legal immigrants from using public benefits; a study in The American Journal of Managed Care® finding that a law to limit surprise medical bills is working; data on Affordable Care Act enrollment showing the effect of subsidies.

Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.

The researchers called for more work to discover specific exposures in patients with leukemia that lead to infections after treatment ends.

The August issue of The American Journal of Managed Care® (AJMC®) featured research on surprise medical billing policies, social determinants of health, and the value of chimeric antigen receptor T-cell therapies, among other topics. Here are 5 findings from research published in the issue.

Parents treated for tobacco addiction within a pediatric office were associated with a significant decline in smoking rates as opposed to standard offices.

Generic drug makers are being accused of blocking a Congressional probe into their pricing practices; Illinois has become the first state to require insurance companies to pay for EpiPens for kids in cases of severe allergic reactions; Tufts Health Plan and Harvard Pilgrim Health will merge to create a new company covering 2.4 million people across New England.

The authors call for more personalized screening protocols to find cancer earlier in younger adults, as well as public health efforts to address obesity.

FDA's approval of entrectinib for neurotrophic tyrosine receptor kinase (NTRK) fusion-positive tumors represents a new paradigm in cancer treatment; It treats a cancer based on a common biomarker seen across different tumors rather than based on the location in the body where the cancer originated. The FDA also gave approval to entrectinib for the treatment of adults with metastatic non–small cell lung cancer whose tumors are ROS1 positive.

Under a proposed rule released today, the agency would require new health warnings on cigarette packages and advertisements, which would feature pictures and images depicting some of the lesser-known health risks, including bladder cancer and heart disease.

Researchers aiming to better understand the role of estrogen in the development of Parkinson disease (PD) and its potential as a treatment found that brain-selective estrogen therapy resulted in motor improvements in male mice with PD-like symptoms.

Researchers showed the potential of combining 2 precision medicines to overcome treatment resistance.

Scientists uncovered a rare, inherited gene mutation, known as RABL3, that raises the risk of pancreatic and other cancers.

Planned Parenthood plans to withdraw from Title X program, amid looming Trump Administration rule changes; a new cure accepted by the FDA for a deadly strain of tuberculosis has been found to have a 90% success rate in a patient trial; opioid distribution to patients has began to change amongst doctors with new recommendations based around set prescribing levels.

Chronic active lesions, which are identified by their darkened outer rims, are associated with more aggressive multiple sclerosis and earlier disability, according to new research from the National Institute of Health.

While air pollution has long been associated with cardiovascular and respiratory diseases, this is believed to be the first longitudinal study of air pollution and emphysema progression.

Timothy R. Smith, MD, RPh, is president and chief executive officer of StudyMetrix Research. He is a fellow of the American College of Physicians and the American Headache Society, a certified physician investigator of the Academy of Clinical Research Professionals, and vice president of the National Headache Foundation. Dr Smith has a special interest in patient and physician issues related to the treatment of headache in primary care. This is part 2 of an interview conducted by an editor from The American Journal of Managed Care®.

Timothy R. Smith, MD, RPh, is president and chief executive officer of StudyMetrix Research. He is a fellow of the American College of Physicians and the American Headache Society, a certified physician investigator of the Academy of Clinical Research Professionals, and vice president of the National Headache Foundation. Dr Smith has a special interest in patient and physician issues related to the treatment of headache in primary care. This is part 1 of an interview conducted by an editor from The American Journal of Managed Care®.

The US Preventive Services Task Force is recommending screening all adults for illicit drug use; Senator Chuck Grassley, R-Iowa, is asking the FDA to perform more unannounced inspections of foreign drug manufacturing facilities; 5 years after Congress passed a law to reduce unneccessary diagnostic imaging tests, the law has yet to be implemented.